# Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

> **NCT04870034** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Colorectal Carcinoma
- Lung Adenocarcinoma
- Malignant Solid Neoplasm
- Pancreatic Carcinoma

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Palbociclib
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT04870034
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-15
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Issues recruiting
- **Last updated:** 2023-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04870034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04870034, "Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04870034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*